<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03981380</url>
  </required_header>
  <id_info>
    <org_study_id>AAAS2808</org_study_id>
    <secondary_id>R01AG058969</secondary_id>
    <nct_id>NCT03981380</nct_id>
  </id_info>
  <brief_title>11C-PIB PET Study in MESA at Columbia University</brief_title>
  <official_title>11C-PIB PET Study in the Multi Ethnic Study of Atherosclerosis at Columbia University</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>José A. Luchsinger</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wake Forest University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will conduct a study of brain positron emission tomography (PET) using
      11C-PIB for the imaging of brain amyloid in 250 participants in the Multiethnic study of
      atherosclerosis (MESA) at Columbia University Irving Medical Center in New York City.
      Participants will be imaged only once with Pittsburgh Compound B (PIB) PET.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center PET study of 11C-PIB. Eligible participants are current participants
      in the MESA study in New York City, without contraindications to MRI or PET procedures. Those
      eligible will have one brain PET scan with 11C-PIB within 12 months of a brain MRI. Vital
      signs will be checked prior to injection of 11C-PIB, 10 minutes after the injection, and
      again at the completion of the PET scan. The primary outcome measure for amyloid will be
      whole brain 11C-PIB SUVR. The relation between exposure groups and amyloid in the brain will
      be analyzed using linear regression.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Whole Brain 11C-PIB SUVR</measure>
    <time_frame>40 to 90 minutes post injection</time_frame>
    <description>Standardized uptake value ratio (SUVR) of 11C-PIB;The extent of Aβ deposition in the brain will be quantified by[11C]PiB uptake visualized by PET using standardized uptake volume ratio (SUVR) of 6 primary cortical areas (i.e., anterior cingulate, prefrontal cortex, lateral temporal cortex, posterior parietal cortex, precuneus cortex, and anteroventral striatum) relative to the uptake in the cerebellum</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Cognitive Impairment</condition>
  <condition>Vascular Diseases</condition>
  <condition>Alzheimer Disease</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>MESA study participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Current participants in the MESA study in New York City, 60 years or older, fluent in English or Spanish, able to participate in the brain imaging study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>11C-PIB</intervention_name>
    <description>Participants will be injected with an intravenous bolus of up to 5-15mCi (370 MBq) (+/-10%) of [11C]PiB (over 5-10 seconds).</description>
    <arm_group_label>MESA study participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current participants in MESA study at Columbia University

          -  60 years or older

          -  Fluent in English and/or Spanish.

          -  Able to participate in all scheduled evaluations and to complete all required tests
             and procedures.

        Exclusion Criteria:

          -  Active treatment for cancer

          -  Any serious medical condition which would prevent long-term participation

          -  Pregnancy

          -  Weight &gt;300 pounds

          -  Participants previously diagnosed or adjudicated to have dementia

          -  Participants unwilling to undergo cognitive testing

          -  Plans to leave the community within five years

          -  Language barrier (speaks other than English, Spanish, Chinese)

          -  Inability to give informed consent or to obtain consent from a Legally Authorized
             Representative (LAR)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Luchsinger, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Medicine and Epidemiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 7, 2019</study_first_submitted>
  <study_first_submitted_qc>June 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>José A. Luchsinger</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Alzheimer Disease</keyword>
  <keyword>Cognitive Impairment</keyword>
  <keyword>11C-PiB</keyword>
  <keyword>Atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Individual participant data (IPD) may be shared at the end of data collection with a mechanism supported by the National Institute on Aging</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

